Regulatory approval
Published by the Health Canada.
Health Canada approved talazoparib as a monotherapy for the treatment of adult patients with a deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated human epidermal growth factor receptor 2 (HER2)-negative locally advanced (not amenable to curative radiation or surgery) or metastatic breast cancer, who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting, unless patients were inappropriate for these treatments.
This is written in the approval
document as:
TALZENNA is indicated in combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Citation
Pfizer Canada ULC. Talzenna (talazoparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00083453.PDF. Revised February 2026. Accessed April 2026.
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organization(s) |
Biomarker(s) |
Cancer type |
Therapy(ies) |
|
|
HC (1)
|
BRCA1 oncogenic variants
|
Prostate Adenocarcinoma |
Enzalutamide,
Talazoparib
|
|
|
HC (1)
|
BRCA1 pathogenic variants
|
Prostate Adenocarcinoma |
Enzalutamide,
Talazoparib
|
|
|
HC (1)
|
BRCA2 oncogenic variants
|
Prostate Adenocarcinoma |
Enzalutamide,
Talazoparib
|
|
|
HC (1)
|
BRCA2 pathogenic variants
|
Prostate Adenocarcinoma |
Enzalutamide,
Talazoparib
|
|
|
HC (1)
|
ATM pathogenic variants
|
Prostate Adenocarcinoma |
Enzalutamide,
Talazoparib
|
|
|
HC (1)
|
ATM oncogenic variants
|
Prostate Adenocarcinoma |
Enzalutamide,
Talazoparib
|
|
|
HC (1)
|
ATR oncogenic variants
|
Prostate Adenocarcinoma |
Enzalutamide,
Talazoparib
|
|
|
HC (1)
|
CDK12 oncogenic variants
|
Prostate Adenocarcinoma |
Enzalutamide,
Talazoparib
|
|
|
HC (1)
|
ATR pathogenic variants
|
Prostate Adenocarcinoma |
Enzalutamide,
Talazoparib
|
|
|
HC (1)
|
FANCA oncogenic variants
|
Prostate Adenocarcinoma |
Enzalutamide,
Talazoparib
|
|
|
HC (1)
|
CHEK2 pathogenic variants
|
Prostate Adenocarcinoma |
Enzalutamide,
Talazoparib
|
|
|
HC (1)
|
CHEK2 oncogenic variants
|
Prostate Adenocarcinoma |
Enzalutamide,
Talazoparib
|
|
|
HC (1)
|
FANCA pathogenic variants
|
Prostate Adenocarcinoma |
Enzalutamide,
Talazoparib
|
|
|
HC (1)
|
MLH1 oncogenic variants
|
Prostate Adenocarcinoma |
Enzalutamide,
Talazoparib
|
|
|
HC (1)
|
PALB2 pathogenic variants
|
Prostate Adenocarcinoma |
Enzalutamide,
Talazoparib
|
|
|
HC (1)
|
PALB2 oncogenic variants
|
Prostate Adenocarcinoma |
Enzalutamide,
Talazoparib
|
|
|
HC (1)
|
MLH1 pathogenic variants
|
Prostate Adenocarcinoma |
Enzalutamide,
Talazoparib
|
|
|
HC (1)
|
MRE11 oncogenic variants
|
Prostate Adenocarcinoma |
Enzalutamide,
Talazoparib
|
|
|
HC (1)
|
RAD51C pathogenic variants
|
Prostate Adenocarcinoma |
Enzalutamide,
Talazoparib
|
|
|
HC (1)
|
RAD51C oncogenic variants
|
Prostate Adenocarcinoma |
Enzalutamide,
Talazoparib
|
|
|
HC (1)
|
MRE11 pathogenic variants
|
Prostate Adenocarcinoma |
Enzalutamide,
Talazoparib
|
|
|
HC (1)
|
NBN oncogenic variants
|
Prostate Adenocarcinoma |
Enzalutamide,
Talazoparib
|
|
|
HC (1)
|
NBN pathogenic variants
|
Prostate Adenocarcinoma |
Enzalutamide,
Talazoparib
|
|